Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Technology, By Application, By Test Location, By Region, And Segment Forecasts, 2023 - 2030

Research Methodology

A three-pronged approach was followed for deducing the infectious disease in vitro diagnostics market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for infectious disease in vitro diagnostics market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of infectious disease in vitro diagnostics market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Infectious Disease In Vitro Diagnostics Market Categorization:

The infectious disease in vitro diagnostics market was categorized into four segments, namely product (Instruments, Reagents, Software Services,), technology (Immunoassay, Molecular Diagnostics, Microbiology), application (MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB And Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19), test location (Point of Care, Central Laboratories,), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The infectious disease in vitro diagnostics market was segmented into product, technology, application, test location,and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The infectious disease in vitro diagnostics market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; South Korea; Australia; Thailand; Brazil; Mexico; Argentina; South Africa; UAE; Saudi Arabia; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Infectious disease in vitro diagnostics market companies & financials:

The infectious disease in vitro diagnostics market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• BD, an American medical technology company, serves clinical laboratories, life sciences researchers, healthcare institutions, and general public. The company manufactures and markets a wide range of devices, diagnostic products, medical supplies, and laboratory equipment. It operates through three business segments: BD Diagnostics, BD Medical, and BD Biosciences. BD Diagnostics provides products for safe collection & transportation of diagnostic specimens and reagent systems & instruments that accurately detect a broad range of infections, infectious diseases, and cancer. The diagnostic systems offer fully automated molecular systems that provide rapid results, have less handson time, and are easy to use.

• BioMérieux SA, a multinational biotechnology company, is a subsidiary of Institute Mérieux. It designs, develops, and manufactures wide range of diagnostic devices for medical industry. It provides diagnostic solutions such as instruments, reagents, and software, which help in determining the source of contamination and disease to improve patient health and product safety. It offers wide range of solutions mainly for clinical diagnostics and industrial microbiology.

• Abbott has four core business segments namely pharmaceuticals, devices, nutrition, and diagnostics. It has research, manufacturing, sales, and distribution facilities. It’s pharmaceuticals segment offers generic medicines for pain, fever, migraine, inflammation, pancreatic disorders, hypertension, cardiovascular & metabolic products, and vaccines. The diagnostic segment offers reagents and tests for various applications. It’s diagnostics portfolio includes technologies, such as polymerase chain reaction, fluorescence in situ hybridization, and DNA & RNA sequencing. The immunoassays and clinical chemistry assays offered by the company are used in the diagnosis of cancer, infectious diseases, cardiovascular diseases, fertility, and therapeutic drug monitoring.

• Quidel Corporation develops & manufactures point-of-care diagnostic solutions for contagious diseases like group A streptococcal infections and influenza. It primarily focuses on developing and marketing diagnostic solutions. These testing solutions mainly focus on women’s health, gastrointestinal diseases, and infectious diseases. It serves its commodities to distributors and end-users for proficient use.

• OraSure Technologies is a U.S.-based company engaged in manufacturing, developing, and distributing oral fluid diagnostic, and other technologies implemented to diagnose or detect severe medical conditions. It focuses on manufacturing and selling various cryosurgical products used for removal of plantar warts and skin lesions. Products of the company are distributing to clinics, hospitals, community-based organizations, and other public health organizations.

• HOLOGIC INC. (GEN PROBE) Gen Probe Incorporated is a part of Hologic Incorporated and is engaged in developing, manufacturing, and marketing of molecular diagnostic products and services. It offers products and services that are mainly used for ensuring transplant compatibility, blood screening, and diagnosing human diseases. It has collaborated and formed strategic alliances with a number of companies including Novartis AG, DiagnoCure, F. Hoffmann-La Roche Ltd., Stratec Biomedical Systems AG, Roka Bioscience, Inc., and Life Technologies Corporation (LTC) to gain access to new markets, products, and technologies.

• CEPHEID (DANAHER), an American multinational company, is a molecular diagnostics company that develops, manufactures, and markets its molecular systems and tests. Its solutions automate time-consuming and complex manual procedures and offers institutions to perform testing for genetic-based disease and organisms. It focuses on applications where rapid, actionable, and accurate test results are required, such as infectious disease and cancer. It is a well-diversified medical and industrial conglomerate. It operates through five business segments: life sciences & diagnostics, test & measurement, industrial technologies, and environmental solutions.

• QIAGEN is a holding company that caters to the biotechnology industry. It was established in 1984 and is headquartered in Germany. QIAGEN provides samples and assay technologies for academic research, applied testing, molecular diagnostics, and pharmaceutical research. The company markets over 500 products including consumable kits and automation systems. QIAGEN products for molecular diagnostics cover the relevant areas of healthcare ranging from early diagnosis of diseases, establishment of diagnosis, diagnostic testing for determination of suitable treatment, and point-ofneed testing. The company’s customers include healthcare providers, pharmaceutical & biotechnology companies, government or industrial customers, and researchers.

• F. Hoffmann-La Roche Ltd is a healthcare company with business operations in the following two divisions: pharmaceuticals and diagnostics. Roche Diagnostics comprises Roche Professional Diagnostics (RPD), Roche Molecular Diagnostics (RMD), Roche Tissue Diagnostics, and Roche Diabetes Care. The product portfolio for Roche Diagnostics includes blood glucose meters, point-of-care testing devices, high-throughput analyzers for commercial & hospital diagnostic laboratories, and reagents & instruments for life sciences research. RMD, a segment of Roche diagnostics, is engaged in development, manufacture, and distribution of tests based on PCR technology & medical diagnostic products, platforms, and services. RMD’s automated platforms and diagnostic tests focus on areas including virology, genomics & oncology, blood screening tests, HPV & CT/NG, and microbiology. It caters to a number of clients, including physicians, researchers, laboratories, hospitals, patients, and blood banks.

• Siemens Healthcare GmbH is a provider of healthcare solutions such as diagnostics (in vitro and in vivo), imaging & therapy systems, clinical products, audiology solutions, and healthcare IT solutions. It also offers medical accessories, OEM component & medical electronics solutions, refurbished systems for medical imaging & therapy, technical, maintenance, and professional & consulting services. Its products and solutions are used in various areas including therapeutic drug monitoring cardiology, organ transplant, urology, infectious disease, diabetes, women's health, surgery, oncology, neurology, and growth disorders.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

Infectious Disease In Vitro Diagnostics Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 - 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Infectious Disease In Vitro Diagnostics Market Report Assumptions:

• The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.